| Company Name: |
ChemShuttle, Inc. |
| Tel: |
0510-83588313-811 18800520310 |
| Email: |
sales@chemshuttle.com |
- Ibiglustat
-
- $30.00
-
2026-05-11
- CAS:1401090-53-6
- Purity: 98.24%
- Supply Ability: 10g
|
| | genz-682452 Basic information |
| Product Name: | genz-682452 | | Synonyms: | GZ/SAR402671;IBIGLUSTAT;VENGLUSTAT;GZ/SAR402671;GZ402671;SAR402671;genz-682452;Ansofaxine Hydrochloride;(S)-QUINUCLIDIN-3-YL (2-(2-(4-FLUOROPHENYL)THIAZOL-4-YL)PROPAN-2-YL)CARBAMATE;Ibiglustat(Genz-682452);Genz-682452-AA;GZ402671 | | CAS: | 1401090-53-6 | | MF: | C20H24FN3O2S | | MW: | 389.49 | | EINECS: | | | Product Categories: | API | | Mol File: | 1401090-53-6.mol |  |
| | genz-682452 Chemical Properties |
| density | 1.30±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:37.5(Max Conc. mg/mL);96.28(Max Conc. mM) | | form | A crystalline solid | | pka | 10.34±0.46(Predicted) | | color | White to off-white | | InChI | InChI=1S/C20H24FN3O2S/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25)/t16-/m1/s1 | | InChIKey | YFHRCLAKZBDRHN-MRXNPFEDSA-N | | SMILES | C(O[C@H]1C2CCN(CC2)C1)(=O)NC(C1=CSC(C2=CC=C(F)C=C2)=N1)(C)C |
| | genz-682452 Usage And Synthesis |
| Uses | Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2]. | | References | [1] Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11(1):20945. Published 2021 Oct 22. DOI:10.1038/s41598-021-00404-5
[2] Peterschmitt MJ, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021;10(1):86-98. DOI:10.1002/cpdd.865
[3] Stojkovska I, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease. Cell Tissue Res. 2018;373(1):51-60. doi:10.1007/s00441-017-2704-y DOI:10.1007/s00441-017-2704-y
[4] Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37(6):1013-22. DOI:10.1007/s10545-014-9724-5 |
| | genz-682452 Preparation Products And Raw materials |
|